Drug · DIN 02230738
HYPERHEP B S/D
ALSO KNOWN AS HEPATITIS B IMMUNE GLOBULIN HUMAN. 5ML VIAL
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since June 26, 2024; first marketed July 8, 1997.
- Drug Identification Number (DIN)
- 02230738
- Company (DIN owner)
- Grifols Therapeutics LlcClayton, North Carolina, United States
- Schedule
- Schedule d
- Dosage form
- Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Hepatitis b immunoglobulin J06BB04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HEPATITIS B IMMUNOGLOBULIN (HUMAN) | 220 UNIT | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 2, 2012: NOC 12991New Drug Submission (NDS) · Manufacturer name change
- June 8, 2005: NOC 7076New Drug Submission (NDS) · Manufacturer and product name change
- February 12, 1997: NOC 3849New Drug Submission (NDS)
Other DINs named HYPERHEP B S/D
- DIN 02379465 · Cancelled Post Market
- DIN 02379473 · Cancelled Pre Market